Agency/Standard Setter Updates OSCaR Fall Educational Workshop Claudia Cooksie, RHIT,CTR October 9, 2015 Portland, Oregon.

Slides:



Advertisements
Similar presentations
Instructions and Reporting Requirements Module 11 Electronic Reporting For Urology Physician Practices May 2013 North Carolina Central Cancer Registry.
Advertisements

Instructions and Reporting Requirements Module 2 Electronic Reporting For Facilities March 2014 North Carolina Central Cancer Registry State Center for.
Hematopoietic and Lymphoid Neoplasm Project. Acknowledgments American College of Surgeons (ACOS) Commission on Cancer (COC) Canadian Cancer Registries.
STAGING MCR Staff Show Me Healthy Women March 27, 2008 Supported by a Cooperative Agreement between DHSS and the Centers for Disease Control and Prevention.
Esophagus, Esophagus GE Junction, Stomach
Nadya Dimitrova Marieta Petkova. 13 Regional cancer registries BNCR: -Established in 1952; cases a year; million population;
Hematopoietic Database and Manual
Cancer Registry Coding Changes for 2014 Presented by the Kentucky Cancer Registry February, 2014.
Collaborative Stage Version An Update From Martin Madera CS Program Administrator.
9 Chapter Nine Neoplasms. © 2013 The McGraw-Hill Companies, Inc. All rights reserved. Learning Outcomes After completing this chapter, you will be able.
Hematopoietic and Lymphoid Neoplasm Project. Primary Site and Histology Rules Peggy Adamo, RHIT, CTR NCI SEER October 2009.
Cancer Staging. What is cancer staging? Staging describes the severity of a person’s cancer based on the extent of the original (primary) tumor and whether.
TRAM Educational Conference September 19, 2014 Meritus Medical Center 1.
Hematopoietic and Lymphoid Neoplasm Project. Background Peggy Adamo, RHIT, CTR NCI SEER September 2009.
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #2 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
Coding Factoids and Frequently Asked Questions Education & Training Team Collaborative Stage Data Collection System Version 1 (CSv2)
1 LUNG. 2 Equivalent Terms, Def, Charts, Tables, Illustrations.
1 MP/H Coding Rules General Instructions MP/H Task Force Multiple Primary Rules Histology Coding Rules 2007.
2010 Hematopoietic and Lymphoid Neoplasm Project Registry Operations and the SEER Program.
Abstract Plus Abstract Plus Overview for Pacific Regional Central Cancer Registry Honolulu, Hawaii March 7, 2009 Software for Abstracting and Coding Cancer.
Cancer Staging.
Putting the Puzzle Together: Breast Collaborative Staging Melissa Riddle, RHIT, CTR October 6, 2012.
CSv2 101 Education & Training Team Collaborative Stage Data Collection System Lecture Version 1.0.
Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,
Cancer Registry Update St. Vincent’s Clay NEFHIMA September 10, 2015.
Data Quality Toolbox for Registrars MCSS Workshop December 9, 2003 Elaine Collins.
1 Myeloma Plasma Cell Disorders (Schema Name: MyelomaPlasmaCellDisorder) V0203.
What’s the Diff? Sue C. Vest, CTR Missouri Cancer Registry This project was supported in part by a cooperative agreement between the Centers for Disease.
VS. CSv2 Changes CSv2 compared to CSv1 Part 1, Section 1.
KCR SPRING TRAINING 2014 New ICD-O-3 Terminology.
2015 CHANGES IN REPORTING REQUIREMENTS AND CANCER CODING INSTRUCTIONS KENTUCKY CANCER REGISTRY SPRING TRAINING 2015 PRESENTED BY FRANCES ROSS.
Hematopoietic and Lymphoid Neoplasm Project. Acknowledgments American College of Surgeons (ACOS) Commission on Cancer (COC) Canadian Cancer Registries.
NPCR/CDC DATA QUALITY EVALUATION AUDIT
Tools to Access the Latest Cancer Statistics Paul Miller Washington Reporting Fellowships program presentation April 15, 2013.
PUBLIC HEALTH DIVISION Oregon State Cancer Registry Abstracting Hematologic Malignancies Stepping Up Your Game LeeLa Coleman, CTR Cancer Data Consultant.
KCR 2014 Spring Training CHANGES IN CODING GRADE.
New Data Items MP/H Task Force Multiple Primary Rules Histology Coding Rules 2007.
2010 Hematopoietic and Lymphoid Neoplasm Project Training, Tools and Resources.
Coding Update 2006 Primary Care Conference March 29, 2006.
Collaborative Staging for Colon Site Specific Factors Tonya Brandenburg, MHA, CTR QA Manager Abstracting and Coding Kentucky Cancer Registry.
Vicki LaRue, CTR KCR Abstractor’s Training February 12,
*Be brief, yet thorough enough to allow recoding of the data fields from the text only! * Use accepted abbreviations from Abstractor’s Manual Appendix.
Copyright, 1996 © Dale Carnegie & Associates, Inc.
ICD-9-CM and ICD-10 Updates and U.S. Adoption of ICD-10-CM Coding Standard: Major Changes in Health Information Coding Practice and Implications for Cancer.
CSv2 for the Hematopoietic Neoplasms 1. 2 This includes five schemas …. Hematopoietic, Reticuloendothelial, Immunopro-liferative and Myeloproliferative.
BY FRANCES ROSS, CTR PRESENTED AT THE NAACCR ANNUAL CONFERENCE JUNE, 2008 Record Consolidation Test with the 2007 Multiple Primary/Histology Rules.
Tumor Marker Phenotype Concordance in Second Primary Breast Cancer Monica Brown, MPH, PhD California Cancer Registry Mary Paré, RN, BS Sutter Cancer Center,
1 Virginia Cancer Registrars Association and Virginia Cancer Registry Annual Meeting October 3, 2007.
Presented at the NAACCR Annual Conference Quebec City June 22, 2010.
1. Multiple Primary and Histology Rules 101 Format of MP/H Materials.
Jennifer Ruhl, BBA, RHIT, CTR Public Health Analyst NCI SEER An innovative approach to improve the quality of data collection for hematopoietic diseases.
The Feasibility of Routine Surveillance of Preinvasive Cervical Cancer in Louisiana Louisiana Tumor Registry Tara Ruhlen, MPH Vivien Chen, MPH, PhD Edward.
Electronic CAP Cancer Checklists and Cancer Registries – A Pilot Project 2009 NAACCR Conference Ken Gerlach, MPH, CTR Castine Verrill, MS, CTR CDC-National.
Using CDC Edits Metafile in the Registry to Support Clinical Trials Recruitment Alan R. Houser, MA, MPH C/NET Solutions Dennis Deapen, DrPH Los Angeles.
What’s New in 2016? For TCR, NPCR, COC April Fritz, RHIT, CTR.
THE IMPORTANCE OF STAGING AND PROGNOSTIC FACTORS IN CANCER CARE
Kentucky Cancer Registry
2018 Solid Tumor Rules: What’s New- Working through the rules
Cancer Reporting Changes for 2017 and 2018
Creating the perfect text…
Tumor Grade.
SEER Case Consolidation Study: Design & Objective
Automated Consolidation of Collaborative Stage Data Items
2018 Updates to ICD-O-3 Histology Coding
North Carolina Central Cancer Registry Electronic Reporting For
What’s New for 8th Edition
Mary Potts, RHIA, CPA, CTR, Manager
PICTURE HERE Eric Chokunonga Zimbabwe Cancer Registry On behalf of:
The Progress of npcr audits What have we done, what have we learned, and where are we going now Click to edit subtitle Click to enter your Division Name.
Presentation transcript:

Agency/Standard Setter Updates OSCaR Fall Educational Workshop Claudia Cooksie, RHIT,CTR October 9, 2015 Portland, Oregon

North American Association of Central Cancer Registries (NAACCR) 2015 Implementation and Guidelines 2015 Implementation Guidelines and Recommendations –Last Revision May 2015 Includes all changes effective with cases diagnosed January 1, 2015 New/Changed Data items Standard Setters Reporting Requirements for 2015 Summary for Software Developers and Vendors Summary for Hospital Cancer Registrars and Reporting Facilities Summary for Central Cancer Registries Guidelines.aspxhttp:// Guidelines.aspx

CHANGED DATA ITEMS-2015 Sex NAACCR Standards Volume II, Version 15 Sex (Item #220) –Code 4 updated Transsexual, NOS –Code 5 added Transsexual, natal male –Code 6 added Transsexual, natal female

CHANGED DATA ITEMS-2015 Country Codes NAACCR Standards Volume II, Version 15 Country codes have been changed for- –Yugoslavia –Czechoslovakia –Brunei –Slovakia –Vanuatu Question-Czechoslovakia was divided into 2 countries in 1993, I saw a code for Slovakia, but not for the Czech Republic. What would that be? Answer- The country code for the Czech Republic is CZE. That is documented in the Appendix X of FORDS 2015 and Appendix B of the SEER Program Coding and Staging Manual 2015

New Survival Data Items NAACCR Standards Volume II, Version 15 Data Item Name –Survival-Date Active Follow-up –Survival-Flag Active Follow-up –Survival-Mos Active Follow-up –Survival-DatePresumed Alive –Survival-Flag Presumed Alive –Survival-Mos Presumed Alive –Survival-Date DX Recode

Hematopoietic Conversion/Edits Document Published 1/9/2015 Incorporated all changes from: –2010 HEME manual and database (cases dx ) –2012 HEME manual and database (cases dx forward) No significant impact on incidence, histology or multiple primaries –Comparison document on SEER website –

HEMATOPOIETIC & LYMPHOID NEOPLASM CODING MANUAL & DATABASE CHANGES Update was released on 1/14/2015 –Diagnostic Confirmation –New section on First Course of Treatment –Appendix F-Non reportable terms (deleted) –Glossary –Obsolete Hematopoietic Histologies –Hematopoietic Conversion/Edits Histology, primary site, and grade

NPCR-CDC-REPORTABILITY DECISIONS HISTOLOGY-2016 forward OSCaR officially notified on September 8, 2015 Use with cases diagnosed 1/1/2016 forward Add new reportable items to your ICD-O-3 manuals OSCaR responsible for educating reporting sources about these new updates. Posted on OSCaR website cDisease/Cancer/oscar/Pages/reporting.aspx cDisease/Cancer/oscar/Pages/reporting.aspx

NPCR-CDC-REPORTABILITY DECISIONS HISTOLOGY-2016 forward Non-invasive mucinous cystic neoplasm (MCN) of the pancreas with high grade dysplasia Replaces the term mucinous cystadenocarcinoma, non-invasive (8470/2) and is REPORTABLE

NPCR-CDC-REPORTABILITY DECISIONS HISTOLOGY-2016 forward Solid pseudopapillary neoplasm of pancreas (8452/3) is synonymous with solid pseudopapillary carcinoma (C25._) and is REPORTABLE

NPCR-CDC-REPORTABILITY DECISIONS HISTOLOGY-2016 forward Based on expert pathologist consultation –Metastases have been reported in some CPEN cases. –With all other pancreatic endocrine tumors now considered MALIGNANT, CPEN will also be considered malignant, until proven otherwise. –Most CPEN cases are non-functioning and are REPORTABLE, using histology code 8150/3, unless the tumor is specified as a neuroendocrine tumor, grade 1 (assign code 8240/3), or neuroendocrine, grade 2 (assign 8249/3)

NPCR-CDC-REPORTABILITY DECISIONS HISTOLOGY-2016 forward Laryngeal Intraepithelial neoplasia, grade III (LIN III),8077/2, C320-C329 is REPORTABLE Squamous Intraepithelial neoplasia, grade III (SIN III), 8077/2, (except for cervix and skin) is REPORTABLE

NPCR-CDC-REPORTABILITY DECISIONS HISTOLOGY-1/1/2016 Mature Teratoma of the testes is malignant and REPORTABLE (9080/3) –Continues to be non-reportable in prepubescent children (9080/0)

NPCR-CDC-REPORTABILITY DECISIONS HISTOLOGY-1/1/2016 ADDITIONAL GUIDANCE IN DETERMINING REPORTABILITY IN MATURE TERATOMA –Adult is defined as post puberty –Pubescence can take place over a number of years –Do not rely solely on age to indicate pre or post puberty status. Review all information (H & P) for documentation of pubertal status –When testicular Teratomas occur in adult males, pubescent status will likely be stated in the EHR –Do not report if unknown whether patient is pre or post pubescence When testicular Teratoma occurs in a male and there is no mention of pubescence, it is likely that the patient is a child, or pre- pubescent and the tumor is benign

ICD-O-3 UPDATES-1/1/2015 Reportability and Behavior Change Carcinoid tumor, NOS, of the appendix (C18.1) must be coded to 8240/3 (effective with cases diagnosed 1/1/2015) Now Reportable and must be coded with a behavior/3

ICD-O-3 UPDATES Recode Changes -1/1/2015 Histology Code 8157 is OBSOLETE in 2015 and use Code 8152 –Two pancreatic tumors, uncertain behavior and malignant Enteroglucagonomas (8157/1 and 8157/3) must be recorded as : Enterogluagonomas NOS (8152/1) and Malignant glucagonomas (8152/3) Subsequent to the conversion of these pancreatic histology codes, –All cases meeting the criteria described above will use the new code “regardless of diagnosis year” as the old codes become obsolete effective 2015

ICD-O-3 UPDATES Issues for 2015 diagnosis year New codes cannot be used for 2015 diagnosis –They are not acceptable histologies for the Collaborative Stage algorithms –Use ICD0-3 Histology code crosswalk to code new terms using the current codes –Appendix A of NAACCR 2015 Implementation Guide explains this, and this is something is worked out with your software vendor

ICD-0-3 Online Version (IARC) Online version of ICD0-3 from International Agency for Research on Cancer at –Useful Tool –For solid tumors-Use ICD-0-3 (2000), aka the “purple book” for solid tumors Do not use ICD-0-3 (2011) For non-solid tumors-Use histology rules from Hematopoietic and Lymphoid Neoplasm Coding Manual and Database –Refer to the NAACCR Guidelines for ICD-0-3 Update implementation for the list of ICD-0-3 changes effective 1/1/2015 –Use the Histology rules in MP/H Manual for solid tumors

Prostate Grade Conversion-2014 forward Coding instructions for Grade (NAACCR Item # 440) were modified for cases diagnosed in 2014 and later Grade code should be consistent with the codes for Gleason score as coded in the CS Site Specific Factors 8 and 10 See SEER Coding Grade at OSCaR Registrar Toolkit

SEER Reportability Clarifications Not Reportable Do not report non invasive mucinous cystic neoplasm (MCN) of the pancreas with low or intermediate grade dysplasia Do not report mature Teratoma of the testis when diagnosed before puberty (benign, 9080/0) –Do not report mature Teratoma when it is not known whether the patient is pre or post pubescent Do not report SIN III of cervix Do not report low grade appendiceal mucinous neoplasm (LAMN), The WHO classification designates LAMN as /1 with uncertain malignant potential

NPCR-CDC Collaborative Stage Transition-NPCR Requirements CS v0205 will continue as the primary staging system method for cases diagnosed beginning January 1, 2015 CDC requires collection of CSv2 data items needed to derive SEER Summary Stage –SSF1-Lung, Pleura and Retinoblastoma –SSF2-CorpusAdenosarcoma, CorpusCarcinoma and CorpusSarcoma –SSF3-Prostate

NPCR-CDC Collaborative Stage Transition- NPCR Requirements Collection prognostic SSF’s –Breast-SSF’s 1-2, 8-9, 11, SSF –Brain/CNS/Intracranial-SSF 1 Required as available, the collection of CSv2 data items needed to derive AJCC, TNM (7 th edition) Schema Discriminator (SSF 25) for applicable sites

NPCR-CDC Collaborative Stage Transition-2016 forward CS Basic data items will go away- CS Ext, CS Eval, LN, LN Eval, Met, Met Eval All new cases will be assigned Directly Coded –SEER Summary Stage 2000 –AJCC TNM (clinical and pathologic) CS Transition Group agreed the SSF’s will continue to be collected through at least 2016

Multiple Primary/Histology Rules Solid Tumor Database Revised MP/H rules to be -1/1/2017 Solid Tumor Database –Standalone reference tool that may be used independent of the rules/manual or a resource for the rules WHO Pathology books (Blue Book) –Recently released 4 th Edition

Remaining Issues Discussed High grade neoplasia (breast) High grade dysplasia (colon) Reportability guidelines for GIST tumors –Sentence added to FORDS 2013 and SEER 2013 Coding manual, which indicate that- GIST tumors and Thymomas are reportable when there is evidence of multiple foci, lymph node involvement or metastasis

Resource Websites

Questions Notecards and place in the “Box” OSCaR QA Team Claudia Cooksie Deborah Towell Leela Coleman Linda Shan Molly Sengvongxay